Advances in translational research of the rare cancer type adrenocortical carcinoma
Adrenocortical carcinoma is a rare malignancy with an annual worldwide incidence of 1–2
cases per 1 million and a 5-year survival rate of< 60%. Although adrenocortical carcinoma is …
cases per 1 million and a 5-year survival rate of< 60%. Although adrenocortical carcinoma is …
[HTML][HTML] Feasibility and Activity of Megestrol Acetate in Addition to Etoposide, Doxorubicin, Cisplatin, and Mitotane as First-Line Therapy in Patients with Metastatic …
Simple Summary Preclinical studies have shown an anti-neoplastic effect of progestins
against adrenal cortical carcinoma. Progestins have a positive effect on patient cenesthesia …
against adrenal cortical carcinoma. Progestins have a positive effect on patient cenesthesia …
[HTML][HTML] The CDK Inhibitor Dinaciclib Improves Cisplatin Response in Nonseminomatous Testicular Cancer: A Preclinical Study
Background: Most patients with testicular germ cell tumors (GCTs) are treated with cisplatin
(CP)-based chemotherapy. However, some of them may develop CP resistance and …
(CP)-based chemotherapy. However, some of them may develop CP resistance and …
Letter re: Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: A population-based study
M Laganà, D Cosentini, GAM Tiberio… - European Journal of …, 2024 - ejcancer.com
Massimo Tiberio, Sandra Sigala and Alfredo Berruti, Letter re: Impact of EDPM on survival of
patients with metastatic adrenocortical carcinoma: A population-based studyIs EDP-M …
patients with metastatic adrenocortical carcinoma: A population-based studyIs EDP-M …
AdrenoCortical Carcinoma: in search of new pharmacological strategies
A Abate - 2024 - iris.unibs.it
Adrenocortical carcinoma (ACC) is a rare malignancy with a dismal prognosis. The
pharmacological approach of ACC is based on mitotane (M) with/without etoposide (E) …
pharmacological approach of ACC is based on mitotane (M) with/without etoposide (E) …